Cargando…

Sodium Oxybate: a Substitute for Alcohol?

Gamma-hydroxybutyrate (GHB) is a neurotransmitter found naturally in the human brain. Sodium oxybate (SO) is the sodium salt of GHB. In 2000 GHB was classified a Schedule I controlled substance, while SO became a Schedule III controlled substance for medicinal use under the Controlled Substances Act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gual, A., López-Pelayo, H., Bruguera, P., Miquel, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564223/ http://dx.doi.org/10.1192/j.eurpsy.2022.144

Ejemplares similares

Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022)

A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder
por: Caputo, Fabio, et al.
Publicado: (2016)

Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration
por: Guiraud, Julien, et al.
Publicado: (2023)

Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial
por: Guiraud, Julien, et al.
Publicado: (2022)

Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate
por: Sarkanen, Tomi, et al.
Publicado: (2014)

Sodium oxybate—a new horizon for symptomatic treatment of RBD?
por: Stefani, Ambra, et al.
Publicado: (2023)

Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union
por: Iranzo, Alex, et al.
Publicado: (2020)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
por: Schneider, Logan D, et al.
Publicado: (2023)

A Case of Off-label Sodium Oxybate in an 11-Year-Old with Narcolepsy
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder
por: During, Emmanuel H, et al.
Publicado: (2023)

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2020)

Long-term Effect of Sodium Oxybate (Xyrem®) in Spasmodic Dysphonia with Vocal Tremor
por: Simonyan, Kristina, et al.
Publicado: (2013)

A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome
por: George, Charles F. P., et al.
Publicado: (2010)

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1
por: Schinkelshoek, Mink S., et al.
Publicado: (2018)

Sodium Oxybate: A Cause of Extreme Involuntary Weight Loss in a Young Lady
por: Noujaim, Michael G., et al.
Publicado: (2019)

O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes
por: Hernest, A, et al.
Publicado: (2023)

Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy
por: Dubow, Jordan, et al.
Publicado: (2022)

Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial
por: Spaeth, Michael, et al.
Publicado: (2012)

Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav(®)) in Sleep Disorders: A Profile of Its Use
por: Heo, Young-A
Publicado: (2022)

Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance–Adams Syndrome
por: Riboldi, Giulietta M., et al.
Publicado: (2019)

REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate
por: Antelmi, Elena, et al.
Publicado: (2021)

Correction to: Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder
Publicado: (2023)

Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2
por: Hesselbacher, Sean, et al.
Publicado: (2018)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

Correction to: Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav(®)) in Sleep Disorders: A Profile of Its Use
por: Heo, Young-A
Publicado: (2022)

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing
por: Feldman, Neil T.
Publicado: (2009)

Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice
por: Drakatos, Panagis, et al.
Publicado: (2017)

Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1
por: Peraita-Adrados, Rosa, et al.
Publicado: (2023)

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity
por: Simonyan, Kristina, et al.
Publicado: (2018)

Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia
por: Spaeth, Michael, et al.
Publicado: (2013)

The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
por: Strunc, Michael J., et al.
Publicado: (2021)

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies
por: Chen, Cuiping, et al.
Publicado: (2021)

Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

The Role of Sodium Oxybate in Idiopathic Hypersomnia: A Case Report Showing Improvement of Excessive Daytime Sleepiness and Reduced Symptoms
por: Vera Ricaurte, Michael, et al.
Publicado: (2023)

Subacute changes in brain functional network connectivity after nocturnal sodium oxybate intake are associated with anterior cingulate GABA
por: Bavato, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6t0e34e6cm9h89lpplu9csri5b